CJC-1295 (No DAC): Complete Research Guide & Chemical Profile

CJC-1295 (No DAC), also known as Mod GRF 1-29, is a synthetic 30-amino acid peptide that functions as a growth hormone-releasing hormone (GHRH) analog. This research compound represents a modified version of the first 29 amino acids of GHRH, with strategic substitutions designed to enhance stability and bioactivity in laboratory settings.

The peptide has a molecular weight of 3,367.97 g/mol and follows the amino acid sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. The "No DAC" designation indicates that this variant lacks the Drug Affinity Complex modification, resulting in a shorter half-life of approximately 30 minutes.

Research laboratories commonly investigate CJC-1295 (No DAC) for its potential to stimulate growth hormone release through the pituitary gland. The tetrasubstituted structure includes four key amino acid modifications that differentiate it from natural GHRH, specifically designed to resist enzymatic degradation while maintaining receptor affinity.

The development of CJC-1295 (No DAC) stems from extensive research into growth hormone-releasing peptides conducted over several decades. Initial studies focused on identifying the minimal active sequence of GHRH required for biological activity, leading to the discovery that the first 29 amino acids contained the essential functional elements.

Research published in the Journal of Clinical Endocrinology & Metabolism has demonstrated that GHRH analogs like CJC-1295 (No DAC) can effectively stimulate growth hormone release in laboratory models. Studies indicate that the peptide maintains high binding affinity to GHRH receptors while exhibiting improved resistance to peptidase degradation compared to native GHRH.

Laboratory investigations have shown that CJC-1295 (No DAC) produces a more physiological pulsatile release pattern compared to other growth hormone secretagogues. Research suggests this pattern more closely mimics natural growth hormone release cycles, making it valuable for studies examining physiological hormone dynamics.

Comparative studies between CJC-1295 (No DAC) and other GHRH analogs have revealed distinct pharmacokinetic profiles. The shorter half-life of the No DAC variant allows for more precise timing in experimental protocols, particularly in studies examining acute hormonal responses.

CJC-1295 (No DAC) exerts its effects through selective binding to growth hormone-releasing hormone receptors located on somatotroph cells in the anterior pituitary gland. This binding initiates a cascade of intracellular signaling events that ultimately result in the synthesis and release of growth hormone.

The peptide binds to G-protein coupled GHRH receptors, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This elevation in cAMP activates protein kinase A, which phosphorylates transcription factors that enhance growth hormone gene expression and protein synthesis.

Research indicates that the four amino acid substitutions in CJC-1295 (No DAC) enhance receptor binding stability without significantly altering the natural binding conformation. The D-alanine substitution at position 2 particularly contributes to peptidase resistance, while maintaining the critical N-terminal tyrosine residue essential for receptor activation.

Laboratory studies demonstrate that CJC-1295 (No DAC) promotes growth hormone release in a pulsatile manner, similar to natural physiological patterns. The 30-minute half-life allows for discrete pulses that can be timed with endogenous growth hormone release cycles, making it particularly useful for research examining natural hormone dynamics.

This pulsatile release pattern is crucial for research applications, as continuous growth hormone elevation can lead to receptor desensitization in experimental models. The shorter half-life of the No DAC variant prevents this issue, allowing for repeated dosing protocols in extended studies.

CJC-1295 (No DAC) is supplied as a lyophilized white powder with a purity standard of ≥99.0% as determined by high-performance liquid chromatography (HPLC). The peptide exhibits good solubility in sterile water, bacteriostatic water, and normal saline solutions commonly used in laboratory settings.

The molecular formula reflects the 30-amino acid sequence with an amidated C-terminus, contributing to its stability profile. The peptide's net charge and hydrophobicity characteristics make it suitable for various analytical techniques including mass spectrometry, HPLC analysis, and protein assays.

Lyophilized CJC-1295 (No DAC) should be stored at -20°C in a dry environment, protected from light. Under these conditions, the peptide maintains stability for extended periods, typically 2-3 years from the date of manufacture. Once reconstituted, the solution should be stored at 2-8°C and used within 2-4 weeks for optimal stability.

Research indicates that the peptide is sensitive to pH extremes and should be reconstituted in solutions with pH values between 6.0-8.0. Freeze-thaw cycles should be minimized to prevent aggregation and maintain biological activity in laboratory applications.

Researchers seeking high-quality CJC-1295 (No DAC) can find verified vendors and third-party tested batches through ChemVerify's comprehensive database. The platform provides detailed analytical data, including HPLC purity reports, mass spectrometry confirmations, and vendor verification status for informed procurement decisions.

ChemVerify's verification process ensures that listed suppliers meet stringent quality standards and provide authentic peptides with proper documentation. Researchers can access comparative pricing, shipping information, and batch-specific analytical certificates through the platform's dedicated CJC-1295 (No DAC) product page at /product/cjc-1295-no-dac.

**What is the difference between CJC-1295 and CJC-1295 (No DAC)?**

CJC-1295 (No DAC) lacks the Drug Affinity Complex modification present in standard CJC-1295, resulting in a significantly shorter half-life (30 minutes vs. 6-8 days). This makes the No DAC variant more suitable for studies requiring precise timing and pulsatile hormone release patterns.

**How should CJC-1295 (No DAC) be reconstituted for laboratory use?**

The lyophilized peptide should be reconstituted with sterile water, bacteriostatic water, or normal saline. Research protocols typically use 1-2 mL of diluent per vial, gently swirling to dissolve without creating foam. The reconstituted solution should be clear and colorless.

**Is CJC-1295 (No DAC) commonly used with other research peptides?**

Research studies frequently investigate CJC-1295 (No DAC) in combination with Ipamorelin, a growth hormone secretagogue that works through different receptor pathways. This combination allows researchers to examine synergistic effects on growth hormone release through complementary mechanisms.

**What analytical methods are used to verify CJC-1295 (No DAC) identity and purity?**

Standard analytical methods include HPLC for purity determination, mass spectrometry for molecular weight confirmation, and amino acid analysis for sequence verification. UV spectroscopy may also be employed for concentration determination and quality assessment.

**What are the optimal storage conditions for long-term stability?**

Lyophilized CJC-1295 (No DAC) should be stored at -20°C in a desiccated environment, protected from light. Reconstituted solutions should be stored at 2-8°C and used within 2-4 weeks. Multiple freeze-thaw cycles should be avoided to maintain peptide integrity.

**How does the short half-life affect experimental design?**

The 30-minute half-life requires careful timing in experimental protocols but allows for precise control over hormone release windows. This characteristic makes CJC-1295 (No DAC) particularly valuable for acute response studies and investigations requiring multiple dosing cycles within the same experimental session.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• Ipamorelin: Complete Research Guide → /learn/ipamorelin
• Sermorelin: Complete Research Guide → /learn/sermorelin-research-guide-chemical-profile

• Read more: RFK Jr. Signals Reversal of Peptide Ban: 14 of 19 Restricted Compounds May Return → https://www.chemverify.com/learn/rfk-jr-signals-reversal-of-peptide-ban-14-of-19-restricted-compounds-may-return
• Read more: Peptide Combinations: Compatibility Research & Evidence Assessment → https://www.chemverify.com/learn/peptide-combinations
• Read more: Complete Peptide Solubility Guide: Solutions for Research Success → https://www.chemverify.com/learn/complete-peptide-solubility-guide-solutions-for-research-success
• Read more: Amino Acid Analysis for Peptides: Complete Guide to Verification Methods → https://www.chemverify.com/learn/amino-acid-analysis-for-peptides-complete-guide-to-verification-methods
• Read more: GMP Peptide Manufacturing: Standards and Quality Control Guidelines → https://www.chemverify.com/learn/gmp-peptide-manufacturing-standards-and-quality-control-guidelines